MedPath

Evaluation of Bilateral Internal Iliac Artery Balloon Occlusion in Placenta Accreta Spectrum Management

Not Applicable
Recruiting
Conditions
Internal Iliac Artery
Balloon Occlusion
Placenta Accreta Spectrum
Interventions
Procedure: Conventional management
Procedure: Bilateral internal iliac artery balloon occlusion
Registration Number
NCT06562712
Lead Sponsor
Tanta University
Brief Summary

This study aims to evaluate the efficacy and safety of bilateral internal iliac artery balloon occlusion in the management of the placenta accreta spectrum.

Detailed Description

Placenta accreta spectrum (PAS) is abnormal placental adhesion beyond superficial myometrium, which includes placenta accreta, placenta increta, and placenta percreta.

However, there is a desire to preserve the uterus and fertility, so alternatives to hysterectomy are needed. Presently, attempts to avoid hysterectomy include reducing intraoperative hemorrhage such as uterine compression sutures, intrauterine balloon tamponade, pelvic artery ligation, and spiral suturing of the lower uterine segment. Intrauterine balloon tamponade may increase CS scar dehiscence, uterine rupture, and infection. Combined with compression sutures, it may induce uterine necrosis.

Placement of balloons in the bilateral internal iliac arteries before caesarean section can reduce uterine artery pressure and intraoperative blood loss during balloon inflation, thus temporarily blocking the main blood supply of the uterus, helping to expose the visual field, shortening the operation time during surgery, and leading to opportunities for timely adjustments to the operative plan during surgery.

Recruitment & Eligibility

Status
RECRUITING
Sex
Female
Target Recruitment
30
Inclusion Criteria
  • Age from 18 to 40 years.
  • Women with placenta accreta spectrum based on ultrasound (US) and/or magnetic resonance imaging (MRI) findings.
Exclusion Criteria
  • Women with a bleeding disorder.
  • History of known allergy to contrast media.
  • Women with Impaired renal function.
  • Emergency cesarean section.
  • Women had severe attack of bleeding before the operation affecting patient's general condition.
  • Women had previous four or more cesarean scars.
  • If ultrasound (US) and magnetic resonance imaging (MRI) suspect the presence of placenta accrete preoperative, then intraoperative the placenta is found to have normal adhesion to the uterine wall, this case will be excluded.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Conventional managementConventional managementPatients will be subjected to conventional management for placenta accreta spectrum.
Bilateral internal iliac artery balloon occlusionBilateral internal iliac artery balloon occlusionPatients will be subjected to bilateral internal iliac artery balloon occlusion for placenta accreta spectrum.
Primary Outcome Measures
NameTimeMethod
Amount of intraoperative blood lossIntraoperatively

The amount of intraoperative blood loss will be calculated with reference to the contents of the suction apparatus and to weight of the surgical pads and the hemoglobin concentration difference, immediate preoperative (the morning of cesarean delivery) and postoperative (immediately after cesarean delivery) hemoglobin levels.

Secondary Outcome Measures
NameTimeMethod
Number of blood products units transfused24 hours postoperatively

Number of blood products units transfused will be recorded.

Hospitalization length28 days postoperatively

Hospitalization length will be recorded from admission till discharge from hospital.

Operation timeFrom the start till the end of surgery

Operation time will be recorded from start till end of surgery.

Incidence of hysterectomy24 hours postoperatively

Incidence of hysterectomy will be recorded.

Intraoperative complicationsIntraoperatively

Intraoperative complications such as bladder injury, ureteric ligature, and uterine atony will be recorded.

Intensive Care Unit (ICU) admission rate24 hours postoperatively

Intensive Care Unit (ICU) admission rate will be recorded.

Trial Locations

Locations (1)

Tanta University

🇪🇬

Tanta, El-Gharbia, Egypt

© Copyright 2025. All Rights Reserved by MedPath